J&J Faces More Risperdal Legal Woes After $2.2 Billion Settlement

A A
Johnson and Johnson’s guilty plea and $2.2 billion settlement with the U.S. government to resolve off-label marketing claims for its anti-psychotic Risperdal leaves the company with more legal fights ahead of it.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00